Abstract
The concept of targeting drug therapy based on plasma concentrations, also called therapeutic drug monitoring (TDM), has been used in the treatment of infectious diseases and other illnesses for decades. A number of clinical trials have demonstrated that drug concentrations are an important factor in response to therapy for HIV, but whether TDM will become a tool for the routine management of HIV infection remains to be determined. The concept of the inhibitory quotient, which integrates drug concentrations and resistance testing, also shows promise in a number of retrospective analyses. Logistical problems still remain with regard to its feasibility, and theoretical issues such as protein binding, variability, and the appropriate time of sampling continue to be debated. A growing body of literature supports the concept of TDM in HIV, but it is important that it be used with other interventions such as resistance testing, adherence monitoring, and patient counseling to be an effective tool in patient management.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.